The Reputation Institute estimates a six-point drop in trust in "Pharma Italia", but the overall score is still high. In the first places AbbVie, Menarini and Angelini
La Repubblica.it – 11 October 2018 – by ANGEL LUPOLI
Confidence in Italian pharmaceutical companies is always very high but the no vax campaigns have begun to affect the reputation of "Pharma Italia", the leading European manufacturer of medicines with over 31 billion in turnover. In the top ten of Pharma RepTrak 2018, the Reputation Institute, world leader in reputation measurement and management, takes first place AbbVie with 72.3 points out of 100, followed by Menarini (71.2 points), Angelini (69.9) , Roche (69.5), Bristol Meyer Squibb (69.1), Lilly (69), Amgen (68.9), Gilead (68.3), Dompé (68.2), Takeda (67.9).
(… continue on The Republic 11 October 2018)
The backward step of the entire sector in public approval - they explain from the Institute which collected 3,200 online interviews throughout Italy - is mainly attributable to the effect of the "undecided" (almost 10 percentage points) which, in strong growth in 2018 – have suspended proceedings against companies especially on issues related to ethics, transparency and the impact of the sector on society.(The sun 24 hours)
Related news
Vaccines. The Senate hosts a conference with Gsk. And the social revolt of the no vax against Grillo is unleashed
Hundreds of comments flooded the Facebook page of Health Minister Giulia Grillo after learning of the international conference "Global Health: Italy as a driver of best practice", organized by Formiche.net in collaboration with GlaxoSmithKline-Gsk, hosted yesterday in the library of Senate. The minister, already attacked for not having promptly put her hand to the Lorenzin law by eliminating all obligations, is now being accused of having "sold out to the drug lobbies" (... continue on dailyhealth of 10 October 2018)
Flexible vaccination obligation: GSK enters the Senate accompanied by the M5s
GlaxoSmithKline (GSK) enters the Senate, a conference organized right during the discussion of the bill on the flexible vaccination obligation.
The 12th Hygiene and Health Commission in the Senate is entrusted with the task, in the drafting session, of developing a new regulatory text on vaccine prevention.
On 2 October, the Commission decided to do so using as a starting point the Legislative Decree 770/2018 signed by Senators Patuanelli and others.
10.00 on 9 October is the deadline granted by the President of the Hygiene and Health Commission Pierpaolo Sileri (M5S) for the presentation of requests for hearings in the Senate, preliminary hearings for the discussion of Legislative Decree 770/2018.
Immediately after this deadline, from 10.30 on the same 9 October, in the Sala degli Atti parlamentari, Library of the Senate "Giovanni Spadolini", the conference "Global Health: Italy as a driver of best practice" will be held, promoted by GlaxoSmithKline.
(… continue on inform X resist)
The initiative, organized in collaboration with GlaxoSmithKline-GSK, is aimed at expressing the strategic dimension for Italy in the context of international cooperation on global health issues.
Guest of honor will be the professor David Salisbury, Associate Fellow Global Health Security at Chatham House The Royal Institute of International Affairs in London.
The institutional greetings will go to Roberto Arditti, editorial director of Formiche and Rino Rappuoli, chief Scientist & Head of External Research and Development (R&D) at GlaxoSmithKline (GSK). They will speak with them Greg French – Ambassador of Australia in Rome, Walter Ricciardi – Member of The Executive Board at the World Health Organization ed Allan Saul – director GSK Vaccines Institute for Global Health.
